Stem-cell treatments are not interchangeable. Verify evidence and authorization for the exact product, condition and route of administration. A facility license does not by itself approve every treatment it advertises.
In this guide
- Separate established treatment from a marketing claim
- Understand Mexico and U.S. authorization separately
- Questions to ask a clinic before discussing price
- Clinical trials need more than a registration number
- Compare costs without assuming effectiveness
- Frequently asked questions
- Sources and further reading
Separate established treatment from a marketing claim
“Stem-cell therapy” covers different products, sources and clinical uses. A recognized use of one cellular product does not validate another clinic’s injections for arthritis, neurological disease, autoimmune conditions or “anti-aging.” Those conditions need separate evidence and specialist assessment.
Cell count alone does not establish clinical benefit. Product identity, manufacturing, delivery and evidence for the proposed indication matter.
Ask an independent specialist to evaluate the proposal before changing established treatment. Request published studies involving the same product, route and condition, with meaningful outcomes and follow-up. Testimonials and before-and-after marketing do not answer those questions.
Understand Mexico and U.S. authorization separately
COFEPRIS administers several kinds of health authorization, including establishment licenses and product or research authorizations. Its current procedures include licensing for regenerative-medicine establishments. Holding such a license does not by itself demonstrate that every advertised treatment is authorized or effective.
Ask for the relevant document numbers, named legal entity, issuing authority, permitted activity and status. A laboratory authorization, import document, advertising permit and clinical-research approval answer different questions. Verify the document that applies to the treatment you are being offered.
U.S. FDA rules are separate. The FDA’s consumer alerts describe risks from unapproved regenerative products. Older statements that only cord-blood stem-cell products have FDA approval must be read with later approvals: in December 2024 the FDA approved Ryoncil for a specific pediatric graft-versus-host disease indication. That approval does not establish approval for general joint, neurological or wellness treatments.
Questions to ask a clinic before discussing price
| Area | Documentation or explanation to request |
|---|---|
| Product identity | Exact product, cell source, manufacturer and batch traceability |
| Proposed use | Diagnosis, intended effect and why this route is proposed |
| Evidence | Studies relevant to the product and indication, including limitations |
| Authorization | Applicable establishment, product and research documentation |
| Quality controls | Donor screening where relevant, testing, handling and storage |
| Risks and alternatives | Known and uncertain risks, other options and informed consent |
| Follow-up | Outcome assessment, adverse-event contact and emergency arrangements |
Swipe or scroll sideways to compare all columns.
A certificate of analysis can describe a batch’s testing. It does not prove that the treatment will improve your condition. Likewise, an intravenous or joint-injection route should not be portrayed as suitable merely because another clinic uses it.
Clinical trials need more than a registration number
If the treatment is described as a clinical trial, obtain the protocol, sponsor, ethics review and applicable regulatory approval. Ask whether your participation matches the eligibility criteria and how costs, monitoring, withdrawal and injuries are handled.
A listing on a trial registry provides information about a study; it is not a blanket government endorsement of a clinic or proof of benefit. Review the actual study documentation with an independent clinician.
Compare costs without assuming effectiveness
There is no defensible standard price comparison between differently sourced products marketed for different conditions. A larger marketed dose does not justify a higher price or a claim of greater potency.
Request separate charges for clinical assessment, product, administration, tests, monitoring, repeated visits and treatment of adverse effects. Add travel and follow-up at home, and clarify deposit and refund terms. Do not assume that insurance covers the proposed treatment or its complications.
Travel convenience should follow clinical assessment. A clinic offering next-day return travel still needs to explain its observation, follow-up and emergency plan. Use the payment guide to check the financial arrangement after the clinical and regulatory questions are resolved.
Frequently asked questions
Does COFEPRIS licensing prove a stem-cell treatment works?
No. An establishment license concerns specified activities at that establishment. Evidence and authorization for the exact treatment and indication need separate verification.
Are higher cell counts more effective?
That cannot be inferred from the count alone. Ask for clinical evidence supporting the exact product, dose, administration route and intended use.
Is every stem-cell treatment approved by the FDA?
No. FDA approvals apply to specified products and indications. They do not extend to unrelated products or broad claims about wellness, arthritis or neurological conditions.